Bristol-Myers Delivers Positive Reblozyl Phase 2 Results
Bristol-Myers Squibb announced on February 23 positive top-line results from a Phase 2 registrational study of Reblozyl for anemia in adults with alpha-thalassemia outside the U.S., with both non‑transfusion-dependent and transfusion-dependent cohorts meeting primary endpoints and all key secondary endpoints. On February 25, RBC Capital initiated coverage with a Sector Perform rating and a $60 price target, citing a deep late-stage pipeline and balanced risk-reward.
Key Points
- 1Announces positive Phase 2 Reblozyl results meeting primary and key secondary endpoints in both patient cohorts.
- 2Highlights clinically meaningful hemoglobin increases and statistically significant transfusion reductions supporting registrational prospects.
- 3Signals balanced investor view after RBC Capital's Feb 25 Sector Perform initiation and $60 price target.
Scoring Rationale
Official positive Phase 2 results and analyst coverage increase significance, but single-company biotech focus limits broader data-science impact.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems
